Introduction {#sec0005}
============

A falsely reactive HIV test result has serious consequences for patients, both emotionally and socially. It may also result in unnecessary initiation of antiretroviral treatment, with potential for side effects and other complications. If later proven to have been false-positive, this can have a negative impact on the perception of, and trust in the health care services by the public. Most falsely reactive HIV serological result are low positive, and can be excluded on the basis of a low positive or indeterminate range, which is appropriate for the local population. In South Africa, HIV testing guidelines for adults and infants over the age of 18 months recommend the use of a series of rapid immunochromatographic assays supplemented by enzyme linked immunosorbent assays (ELISA) in case of discrepant rapid results \[[@bib0005]\].

Case presentation {#sec0010}
=================

The patient was a 35 year old Nigerian man, living in South Africa, who had an unremarkable medical history until 2012, and described himself as previously fit and healthy. Regular screening for HIV at the local community health care clinic had been negative, including three weeks prior to his hospital admission. He denied recent flu-like symptoms or treatment for sexually transmitted infections. He did not use regular medications, traditional medicine, vitamins or dietary supplements. He had no history of HIV vaccine exposure or antiretroviral drug use for pre- or post-exposure prophylaxis. In June 2012, he had a subtotal hemi-mandibulectomy for an ameloblastoma, a benign odontogenic tumor of the mandible \[[@bib0010]\]. This was done in Nigeria, according to the patient\'s self-reported history, but there is neither a histology report nor access to the specimen to confirm the diagnosis. After moving to South Africa, he experienced surgical site complications, and was admitted for replacement of the mandibular reconstruction plate. In 2019, as part of his pre-surgical assessment and workup, he had blood taken for HIV screening. During the operation, one of the surgeons sustained a needle-stick injury, and the virology laboratory was contacted to enquire about the results of the HIV test requested on admission.

His regular partner was then pregnant and had tested HIV negative multiple times during antenatal care visits, including a week before the patient's admission to hospital. He reported concurrent, consistently protected casual intercourse with multiple other female partners up until two to three weeks prior to the current admission but did not report any intravenous drug use or intercourse with men.

Serological screening for HIV-1 and HIV-2 infection was done according to the routine virology testing algorithm at the National Health Laboratory Service (NHLS) Tygerberg laboratory. The 4th generation Elecsys HIV combi PT assay on the Roche COBAS®e 601 analyser (Roche Diagnostics, Mannhein, Germany) showed a reactive result with a high signal to cut-off ratio of 478. However, confirmatory serology using the HIV Ag/Ab Combo assay on the Abbott Architect i2000SR analyser (Abbott Laboratories, Wiesbaden, Germany) was non-reactive with a signal to cut-off ratio of 0.71. Both assays were repeated on four independently obtained samples, obtained over a period of five days, as well as 12 days after the first sample, with similar values obtained ([Table 1](#tbl0005){ref-type="table"}). The Roche Elecsys HIV combi PT assay is a sandwich electrochemiluminecence (ELICA) serological assay \[[@bib0015]\]. It captures HIV-1 and HIV-2 antibodies and p24 antigens, using biotinylated and ruthenylated conjugates (anti-p24 antibodies, HIV-specific recombinant antigens/ HIV-specific peptides) to form sandwich complexes, thereafter streptavidin-coated microparticles are added to capture the complexes. A signal is generated from the electrochemiluminescent reaction and the assay readout is light, emitted by the ruthenium complexes when a voltage is passed through the reaction. This signal is compared to a cut off value obtained by calibration of the instrument, giving the signal to cut off ratio (S/CO) \[[@bib0015]\]. The Abbott HIV Ag/Ab Combo assay (Abbott Laboratories) employs a similar chemiluminescent principle.Table 1Serological results.Table 1Date: April 20195/49/49/410/410/417/4Sample ID123456Instrument /platformAssay/ testCOBAS e 601Elecsys®HIV combi PTRRRRR**S/CO:478488493415471**Abbott Architect i2000SRHIV Ag/Ab ComboNRNRNRNRNR**S/CO:0.710.790.770.660.7**Bio-RadBio-Rad GenscreenNULTRA HIV Ag/Ab**S/CO:0.27**Rapid testVisitect HIV1/2 RapidNRRapid testAlere™ HIV ComboNRapid testAbon HIV 1/2/O Tri-lineNRRapid testADVANCED QUALITY™NRRapid Anti-HIV(1&2)

Diagnoses considered at this stage included acute HIV infection/seroconversion, a second window period, HIV-2 infection (with variable sensitivity for HIV-1 and 2 on the different testing platforms accounting for the discrepant results), or false positive results. A second diagnostic window period in HIV serological testing describes a time period where a fourth-generation assay will be nonreactive because the antigen (p24) component becomes undetectable, but before the antibody component is high enough to be detected \[[@bib0020]\]. False positive results may be caused by non-specific binding of other immunoglobulins in the sample to the target antigens or antibodies or to one of the other components of the assay. Cross-reacting immunoglobulins may represent antibodies to a different antigen, rheumatoid factor or be due to polyclonal activation.

Acute HIV infection was excluded via molecular testing, using the COBAS®AmpliPrep/ COBAS®TaqMan HIV-1 Quantitative Test V2.0 (Roche Diagnostics), showing a viral load of lower than detectable. Qualitative total nucleic acid testing for HIV-1 with the HIV-1 Qualitative Test V2.0 (Roche Diagnostics) also yielded a negative result. (See [Table 2](#tbl0010){ref-type="table"} for details). Considering the patient's country of origin, a diagnosis of HIV-2 was considered, and an EDTA whole blood sample was tested for HIV-2 via polymerase chain reaction (PCR), using the Alere™ Q analyser HIV 1 /2 Detect test (Roche Diagnostics), which gave negative results for both HIV 1 group M/N, group O and HIV-2.Table 2Molecular results.Table 2Date: April 20195/49/49/410/410/417/4Sample ID123456Instrument /platformAssay/ testCOBAS®AmpliPrep/HIV-1 QuantitativeLDLLDLCOBAS® TaqManTest V2.0COBAS®AmpliPrep/HIV-1 QualitativeNDNDCOBAS®TaqManTest V2.0Alere qHIV-1/2NDDetect (quant PCR)

In order to exclude established HIV infection with low or variable antibody levels, as a result of undisclosed treatment with antiretrovirals, or as a possible elite controller of HIV, additional serological testing was performed. A variety of rapid immunochromatographic tests were performed on the patient\'s samples, all with negative results (see [Table 1](#tbl0005){ref-type="table"} for details). An alternative 4th generation serological assay, the GS Bio-Rad HIV Combo Ag/Ab Assay (Bio-Rad Diagnostics, Marnes-la-Coquette, France) was used as a tiebreaker which too produced a negative result. CD4 count testing was performed with a result of 1 454 cells/microliter.

To investigate a non-specific cross reaction related to the Roche Elecsys®HIV combi PT assay principle, such as non-specific cross-linking of conjugate, tests based on the same principle but for other serological markers for which the patient might be negative, were investigated on the same Roche COBAS®e 601 analyser. These included hepatitis A IgM, hepatitis B surface, and core IgM and hepatitis C antibodies as well as hepatitis B surface antigen. The sample tested negative with all these assays, suggesting that the false cross-reactivity was likely restricted to a component of the HIV combi PT assay.A series of dilutions of one of the patient samples were made using the Roche 'Dil Uni' reagent and tested on the Roche screening HIV assay. Results reflected a linear dilution of the reactive component as follows: Undiluted sample: reactive (S/CO 492.6); sample diluted 1:10: reactive (S/CO 48.8), sample diluted 1:100: reactive (S/CO 4.22), sample diluted 1:1000: reactive (S/CO 1.01). Serial dilution has been used as a method of distinguishing false positive results due to cross reacting antibodies from true positive results. In incidence surveys, dilution is used to alter the sensitivity of antibody tests to detect recent HIV infection \[[@bib0025]\]. In principle, during early HIV infection, lower antibody titers means that reactivity can be diluted out earlier than for samples with high titers. Low avidity, broadly reactive antibodies produced to infectious antigens other than HIV can also cause a false positive result in serological testing for HIV and may theoretically become negative on dilution, as this makes a functionally less sensitive assay \[[@bib0025]\]. It is significant in this case that the sample tested positive on repeated dilutions, indicating that this false positive result was most likely not due to this type of low avidity antibody response. This finding is supported by repeatedly positive results, with a similar S/CO result on repeat testing 12 days after the initial sample was taken, making a transient response to another antigen less likely.

Cross reacting Schistosoma antibodies remains a possible cause, as the patient tested positive on an immunofluorescent assay for anti-cercarial IgM and IgG antibodies. This has been described as a possible cause of falsely reactive fourth generation immunoassays in other African populations \[[@bib0030]\]. Other common causes of cross reactivity include autoimmune disease and rheumatoid factor; screening tests for these two conditions were negative. To further investigate specific cross reactive antibodies, the patient's sample was tested with the Geenuis HIV 1/ 2 confirmatory assay (Bio-Rad Diagnostics, Marnes-la-Coquette, France) which is a 'rapid' recombinant immunochromatographic test used for the confirmation and differentiation of individual antibody responses to HIV-1 and 2 \[[@bib0035]\]. Criteria for interpretation of a positive test result for HIV -1 include the presence of any two bands of the HIV-1 test lines with at least one envelope band positive (gp160 or gp41), while a positive test for HIV-2 must include both HIV-2 bands (gp36 and gp140). Testing of this patient's sample using this assay produced a faint band in the gp41 test line (HIV-1 group M and O envelope peptides) but no other bands were produced, indicating an indeterminate result. This correlates with findings from a report of a more than five million samples collected over four years from low risk blood donors, showing that the most common profile of false positive HIV-1 western blot tests were antibodies to envelope only \[[@bib0040]\].

Patient samples were sent to the screening assay manufacturer for analysis and were found to be falsely reactive to one of the seven HIV specific antigens the test employs. It was determined that the COI (cut off index) of these samples was around 400, and highly reactive against a particular synthetic peptide but non-reactive against the recombinant antigens. The clinicians involved were advised that it was safe to stop post exposure prophylaxis. The patient was informed about these false positive results and advised to relate this history to future health care providers.

Discussion {#sec0015}
==========

Reasons for false reactive serological tests can be classified as pre-analytical, which include sample swaps or sample contamination \[[@bib0045]\]; analytical, such as false reactive results due to cross reacting antibodies; or post-analytical, when non-reactive results are incorrectly reported as reactive. When assays are performed in settings that are very different from the population in which they were validated, specificity may be lower than expected. For instance, poor specificity has been reported for HIV and hepatitis C virus serological assays in tropical countries \[[@bib0050]\].

Most false reactive results, however, are low positive and could be excluded based on a low positive/indeterminate range, appropriate for the local population. This high-positive false positive result (more than 400 times the cut-off for positivity) on the screening assay is therefore very unusual. It should be emphasized that all laboratory-based HIV diagnoses require confirmatory testing on a separate independent serological platform and require an independently collected sample. In this case, independently collected samples all showed high positive values on the screening assay, but negative values on the confirmatory assay.

Multiple biological reasons for false reactive serology have been reported, which include polyclonal activation during systemic infections, molecular mimicry with other infectious agents, pregnancy, vaccination and various malignancies \[[@bib0055], [@bib0060], [@bib0065]\]. No prior case reports regarding ameloblastoma and false positive HIV serological results have been published, although a variety of other malignancies have been implicated in generating false positive HIV results \[[@bib0060]\]. The reason for the falsely reactive screening assay result remains unknown at present, although the possibility of cross reactivity with schistosomiasis antibodies or antibodies produced towards his previously excised ameloblastoma, or another antigen remains.

Conclusion {#sec0020}
==========

HIV serological diagnosis in adults and children older than 18 months necessitates confirmatory testing to exclude assay-specific false reactivity and the testing of an independently collected sample to avert sample-associated causes of false positivity such as mislabelling, transient cross-reactivity or on-instrument contamination. Although the cause for this high positive assay-specific false reactive result could not be elucidated fully, this case highlights the indispensable need for confirmatory HIV serological testing and the use of independent serological and molecular assays as tiebreakers in investigating discordant results.
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